Signatera is a personalized, tumor-informed assay, optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer. Results are based on the unique signature of a patient’s tumor by tracking mutations at the source and enabling accurate monitoring of disease over time. Clinically validated in multiple cancer types, Signatera is covered by Medicare for colorectal cancer (CRC), muscle invasive bladder cancer (MIBC), and stage IIb and higher breast cancer in both the adjuvant and surveillance setting as well as monitoring response to immunotherapy treatment for any solid tumor. Discover more at: natera.com/oncology